RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance

Blood
Catherine Roche-LestienneFi-LMC group

Abstract

Acquired molecular abnormalities (mutations or chromosomal translocations) of the RUNX1 transcription factor gene are frequent in acute myeloblastic leukemias (AMLs) and in therapy-related myelodysplastic syndromes, but rarely in acute lymphoblastic leukemias (ALLs) and chronic myelogenous leukemias (CMLs). Among 18 BCR-ABL+ leukemias presenting acquired trisomy of chromosome 21, we report a high frequency (33%) of recurrent point mutations (4 in myeloid blast crisis [BC] CML and one in chronic phase CML) within the DNA-binding region of RUNX1. We did not found any mutation in de novo BCR-ABL+ ALLs or lymphoid BC CML. Emergence of the RUNX1 mutations was detected at diagnosis or before the acquisition of trisomy 21 during disease progression. In addition, we also report a high frequency of cryptic chromosomal RUNX1 translocation to a novel recently described gene partner, PRDM16 on chromosome 1p36, for 3 (21.4%) of 14 investigated patients: 2 myeloid BC CMLs and, for the first time, 1 therapy-related BCR-ABL+ ALL. Two patients presented both RUNX1 mutations and RUNX1-PRDM16 fusion. These events are associated with a short survival and support the concept of a cooperative effect of BCR-ABL with molecular RUNX1 abnormalities on t...Continue Reading

References

Oct 3, 1999·Nature Genetics·M L Cleary
Jul 19, 2002·Cancer Cell·D Gary Gilliland, Martin S Tallman
Oct 10, 2003·The New England Journal of Medicine·John M Goldman, Junia V Melo
Feb 26, 2004·Blood·Bruno Calabretta, Danilo Perrotti
Sep 9, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Xavier ThomasDenis Fiere
Jul 15, 2005·Genes, Chromosomes & Cancer·Ikuya SakaiMasaki Yasukawa
Nov 24, 2005·Hematology·Oliver G Ottmann, Barbara Wassmann
Aug 11, 2006·Genes, Chromosomes & Cancer·Sawcène HazourliJosée Hébert
Mar 16, 2007·Proceedings of the National Academy of Sciences of the United States of America·Cornelius MiethingJustus Duyster
Jul 26, 2007·Haematologica·Fernando P G SilvaMicheline Giphart-Gassler
Sep 8, 2007·Stem Cells·Lena MotodaYoshiaki Ito

❮ Previous
Next ❯

Citations

Feb 14, 2012·Current Hematologic Malignancy Reports·Tomasz Skorski
Jul 2, 2010·The Journal of Clinical Investigation·Danilo PerrottiTomasz Skorski
Jan 11, 2012·The Journal of Clinical Investigation·Christian SchürchAdrian F Ochsenbein
Dec 23, 2010·Future Oncology·Etienne De BraekeleerMarc De Braekeleer
Jan 11, 2014·Current Hematologic Malignancy Reports·Paolo Neviani
Mar 5, 2016·Oncoimmunology·Stefanie Andrea Erika HeldPeter Brossart
Aug 5, 2010·Cancer Genetics and Cytogenetics·Katsuya YamamotoToshimitsu Matsui
Nov 5, 2011·British Journal of Haematology·Francois P DuhouxUNKNOWN Belgian Cytogenetic Group for Haematology and Oncology (BCG-HO)
Mar 17, 2010·Genes, Chromosomes & Cancer·Christa Fonatsch
Aug 25, 2015·Clinical Lymphoma, Myeloma & Leukemia·Simona SoveriniGiovanni Martinelli
Jun 2, 2012·Blood·Rüdiger Hehlmann
Feb 24, 2011·Blood·Francesca AguiloHans-Willem Snoeck
Jul 13, 2017·Journal of Cancer Prevention·Aliasghar KeramatiniaAbolfazl Movafagh
Feb 28, 2014·Molecular Medicine Reports·Yin-Yin XiaYing-Xiong Wang
Nov 18, 2018·Cellular Oncology (Dordrecht)·Xin Xu, Björn Schneider
Jun 19, 2019·Leukemia·Susan BranfordUNKNOWN International CML Foundation Genomics Alliance
Apr 16, 2020·International Journal of Molecular Sciences·Amelia CasamassimiCiro Abbondanza
Dec 11, 2019·International Journal of Molecular Sciences·Luana BavaroSimona Soverini
May 5, 2021·Leukemia & Lymphoma·Shady Adnan-AwadSatu Mustjoki

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.